Researchers at Harvard’s Beth Israel Deaconess Medical Center (BIDMC) will attempt to verify the pharmacokinetic and pharmacological properties of PT-401, DNAPrint’s lead product in development.
“We expect that the research will provide data that will be included in the company’s anticipated future filings with the FDA for PT-401, a ‘Super EPO’ that is a more powerful version of the existing drug,” stated Dr Hector Gomez, chairman and chief medical officer of DNAPrint Genomics.
Under the terms of the agreement, DNAPrint Genomics will provide Beth Israel Deaconess $600,000 in funding for the research. One half of the amount has already been paid with $150,000 due on January 1st, 2007. The balance is to be paid upon completion of the research.
In April 2005, DNAPrint Genomics announced that it had received an exclusive worldwide license from BIDMC to develop PT-401. According to the company, the EPO market is growing at an average annual rate of 21%.